🔗 Share this article

While the US undertakes unprecedented adjustments to its immunization schedules, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on Covid vaccines in the pandemic and has concentrated on possible fatalities after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Program

Health officials were set to unveil sweeping revisions to the childhood immunization program in December, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would place the US at odds with much of the world with no evidence for improved outcomes. The announcement has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to speak at the event. She was just designated interim head of the FDA’s CDER, the fifth individual to head the division this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the drug and biologics branches as Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for ending specific childhood vaccine recommendations in the US in order to be more in line with Denmark, a society with nationalized medicine and a population roughly the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – usually the purview of Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Expertise

Høeg has no obvious experience in pharmaceutical research, approval processes or administrative roles, which has been typical for previous heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a major agency. She is not an expert in drug approvals.”

Former commissioners of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who led CBER have had.”

CDER has an enormous workload at the agency, Woodcock emphasized.

“The public just pays attention on the new drug program, but the generic program authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and more, and all of those need to be managed,” she said. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a substantial leadership component to the job, which manages over 5,000 personnel. “It’s a huge administrative position, if you perform it correctly,” she said.

Response and Contentious Initiatives

When asked about inquiries about Høeg’s credentials and whether this selection represents more teamwork among FDA leaders on vaccines, a press secretary responded that the “concerns stem from inaccurate assumptions”.

“Her resume is consistent with the functions of her job,” the official stated, pointing to the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's recently launched priority voucher program, a controversial expedited medication authorization process that allegedly concerned her former heads. “How are these medications being picked for this fast-track system? Who is making the choices?” Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

In general, he said, “the agency seems to be moving towards laxer regulations of all drugs, with the exception of shots.”

Documented Track Record on Immunizations

Concerning vaccines, Høeg has a clearer, if problematic, track record, Howard said. She released a research paper using unverified crowd-sourced reports to determine the rate of heart inflammation after COVID-19 vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the incoming government encompassed revising regulations for novel immunizations and ending “unnecessary” vaccines, she remarked after the election on a podcast. At the agency, Dr. Høeg has according to sources suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who begins with her preconceived notions and reverse-engineers to accommodate the science in a very disingenuous, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|